- Home
- CREV vs KLTO Comparison
CREV vs KLTO Comparison
Compare CREV & KLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CREV
- KLTO
- Stock Information
- Founded
- CREV 2007
- KLTO 2019
- Country
- CREV Ireland
- KLTO United States
- Employees
- CREV N/A
- KLTO N/A
- Industry
- CREV
- KLTO
- Sector
- CREV
- KLTO
- Exchange
- CREV Nasdaq
- KLTO NYSE
- Market Cap
- CREV 6.0M
- KLTO 5.9M
- IPO Year
- CREV N/A
- KLTO N/A
- Fundamental
- Price
- CREV $4.90
- KLTO $1.34
- Analyst Decision
- CREV
- KLTO
- Analyst Count
- CREV 0
- KLTO 0
- Target Price
- CREV N/A
- KLTO N/A
- AVG Volume (30 Days)
- CREV 691.3K
- KLTO 22.5M
- Earning Date
- CREV 05-14-2025
- KLTO 08-15-2025
- Dividend Yield
- CREV N/A
- KLTO N/A
- EPS Growth
- CREV N/A
- KLTO N/A
- EPS
- CREV N/A
- KLTO N/A
- Revenue
- CREV $39,261,077.00
- KLTO N/A
- Revenue This Year
- CREV $40.76
- KLTO N/A
- Revenue Next Year
- CREV $86.18
- KLTO N/A
- P/E Ratio
- CREV N/A
- KLTO N/A
- Revenue Growth
- CREV 41.52
- KLTO N/A
- 52 Week Low
- CREV $2.00
- KLTO $0.11
- 52 Week High
- CREV $14.19
- KLTO $3.91
- Technical
- Relative Strength Index (RSI)
- CREV 70.80
- KLTO N/A
- Support Level
- CREV $2.51
- KLTO N/A
- Resistance Level
- CREV $4.26
- KLTO N/A
- Average True Range (ATR)
- CREV 0.74
- KLTO 0.00
- MACD
- CREV 0.27
- KLTO 0.00
- Stochastic Oscillator
- CREV 83.07
- KLTO 0.00
About CREV Carbon Revolution Public Limited
Carbon Revolution PLC is an Australian-based technology company manufacturing carbon fiber wheels. It is an OEM supplier and a world-wide manufacturer of lightweight technology carbon fibre wheels to the automotive industry. The Company supplies wheels to OEMs across the globe for luxury and high-performance vehicles and SUVs, and is developing wheels for electric vehicles under contract for its OEM customers. The company generates maximum revenue Internationally.
About KLTO KLOTHO NEUROSCIENCES INC
Klotho Neurosciences Inc is in the development of essential medicines for the treatment of chronic diseases: Cancer, Cardiovascular, and Neurodegenerative disorders. The Company currently has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Company pipeline includes KLTO 101, KLTO 202, KLTO 301.